|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/496 | |
| A61K 31/506 | |||
| A61K 31/401 | |||
| A61K 31/404 | |||
| A61K 31/4418 | |||
| A61K 31/4439 | |||
| A61K 31/47 | |||
| A61P 35/00 |
| (11) | Patento numeris | 3541387 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 17804304.8 |
| Europos patento paraiškos padavimo data | 2017-11-14 | |
| (97) | Europos patento paraiškos paskelbimo data | 2019-09-25 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-04-21 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/IB2017/057097 |
| Data | 2017-11-14 |
| (87) | Numeris | WO 2018/092020 |
| Data | 2018-05-24 |
| (30) | Numeris | Data | Šalis |
| 201662422144 P | 2016-11-15 | US | |
| 201762479391 P | 2017-03-31 | US |
| (72) |
FERRETTI, Stephane, CH
GUERREIRO, Nelson, CH
JEAY, Sebastien, CH
JULLION, Astrid, CH
MEILLE, Christophe, CH
WUERTHNER, Jens, CH
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | DOSE AND REGIMEN FOR HDM2-P53 INTERACTION INHIBITORS |
| DOSE AND REGIMEN FOR HDM2-P53 INTERACTION INHIBITORS |